Krebs Ilse, Krepler Katharina, Stolba Ulrike, Goll Alexandra, Binder Susanne
Department of Ophthalmology, Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery, Rudolf Foundation Clinic, Juchgasse 25, Vienna, Austria.
Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):237-43. doi: 10.1007/s00417-007-0651-0. Epub 2007 Aug 3.
The objective of the study was to investigate whether combined treatment with photodynamic therapy (PDT) and triamcinolone acetonide intravitreally applied is superior to PDT alone in eyes with retinal angiomatous proliferation (RAP).
Between July 2004 and June 2005 eyes with RAP in age-related macular degeneration were included in a prospective study and were treated with 4 mg of triamcinolone acetonide followed by PDT (group 1). Eyes with RAP treated with PDT alone before June 2004 were retrospectively reviewed (group 2). Distance visual acuity (VA) with Early Treatment Diabetic Retinopathy Study (ETDRS) charts, greatest diameter of the lesion (measured by fluorescein angiography), and retinal thickness (measured by optical coherence tomography) were performed at baseline and at 6 weeks, 3 months, 6 months and 12 months thereafter.
Fifty-eight eyes in 58 patients were included: 27 eyes in the combined treatment group and 31 eyes in the PDT monotherapy group. The groups were comparable with regard to age, gender and RAP stage. VA decreased from 65.6 to 52.0 and from 60.7 to 44.0 letters, and lesion size increased from 3.2 mm to 3.5 mm and from 3.3 mm to 3.5 mm in the combined and monotherapy groups respectively. There was a trend towards a better outcome in the combined group. Significantly (p = 0.01) fewer complications occurred in the combined group (22.2%) than in the monotherapy group (54.8%).
No significant differences could be found in the time course of distance VA, retinal thickness, and lesion size between the PDT monotherapy group and the combined PDT and IVTA group. However, significantly fewer complications occurred in the combined treatment group. New therapeutic strategies might be required in RAP lesions, probably including therapy with anti-angiogenic agents.
本研究的目的是调查光动力疗法(PDT)联合玻璃体内注射曲安奈德治疗视网膜血管瘤样增生(RAP)的眼睛是否优于单纯PDT治疗。
2004年7月至2005年6月期间,将年龄相关性黄斑变性伴RAP的眼睛纳入一项前瞻性研究,先给予4mg曲安奈德治疗,随后进行PDT(第1组)。回顾性分析2004年6月之前单纯接受PDT治疗的RAP眼睛(第2组)。使用早期糖尿病视网膜病变研究(ETDRS)视力表测量远视力(VA),通过荧光素血管造影测量病变的最大直径,并通过光学相干断层扫描测量视网膜厚度,在基线时以及之后的6周、3个月、6个月和12个月进行测量。
纳入了58例患者的58只眼睛:联合治疗组27只眼睛,PDT单一疗法组31只眼睛。两组在年龄、性别和RAP分期方面具有可比性。联合治疗组和单一疗法组的VA分别从65.6降低至52.0和从60.7降低至44.0字母,病变大小分别从3.2mm增加至3.5mm和从3.3mm增加至3.5mm。联合治疗组有更好结局的趋势。联合治疗组(22.2%)的并发症明显(p = 0.01)少于单一疗法组(54.8%)。
PDT单一疗法组与PDT联合玻璃体内注射曲安奈德组在远视力时间进程、视网膜厚度和病变大小方面未发现显著差异。然而,联合治疗组的并发症明显较少。对于RAP病变可能需要新的治疗策略,可能包括抗血管生成药物治疗。